About Chembio
Chembio is a Healthcare company based in Medford (United States) founded in 1986, and was acquired by Biosynex in January 2023. It operates as a proprietary immunoassay platform is utilized for infectious disease diagnostics. The company has 213 employees. Chembio has completed 1 acquisition, including Orangelife Comercio E Industria. Its chief executive is Richard Eberly. Chembio offers products and services including DPP HIV-Syphilis Assay, DPP HIV 1/2 Assay, SURE CHECK HIV Self-Test, DPP Zika IgM/IgG System, and Advin COVID-19 Antigen Test. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Viral. Its legal entity is Chembio Diagnostics, Inc. Its competitors include Souzhou Ribo Life Science, PathoQuest, Quantalife, Senzo and Hememics Biotechnologies and 3 more; 7 of its 8 listed competitors have raised funding.
Company details
Chembio Diagnostics, Inc. was established in 1986 in Medford, United States, within the medical diagnostics sector. Rapid tests for infectious diseases, including two FDA PMA-approved, CLIA-waived HIV assays, are produced using the patented Dual Path Platform technology. In the U.S., these HIV tests are distributed by Alere, Inc. Internationally, the HIV STAT-PAK line is supplied to government and donor-funded programs through direct sales and distributors.
- Headquarters Medford, United States
- Employees 213
- Stage Public
- SectorsHealthcare
- Website chembio.com
- Social LinkedIn X Facebook
- Acquired by Biosynex (Jan 2023)
- Legal Name Chembio Diagnostics, Inc.
Products & Services of Chembio
Chembio offers a comprehensive portfolio of products and services, including DPP HIV-Syphilis Assay, DPP HIV 1/2 Assay, SURE CHECK HIV Self-Test, DPP Zika IgM/IgG System, and Advin COVID-19 Antigen Test.
Rapid test for detecting HIV and syphilis in blood samples.
Assay for identifying HIV types 1 and 2 quickly and accurately.
Home-based test kit for HIV detection with easy user instructions.
System for detecting Zika virus antibodies in clinical settings.
Antigen test for rapid COVID-19 detection at home or point-of-care.
Funding Insights of Chembio
- Total Rounds 6
- Last Round Debt – Conventional — $20M
- First Round $2.84M
(Jun 2007)
- Investors Count 2
All 6 funding rounds of Chembio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in Chembio
Chembio has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Biosynex and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Professional rapid diagnostic tests for diseases are manufactured by Biosynex. | 2005 | biosynex.com | Strasbourg, France |
Investor details for Chembio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Chembio
24 people are tracked at Chembio (12 in leadership, 12 in team); the tracked headcount is 213.
| Name | Role | Group |
|---|---|---|
Richard Eberly | CEO | Leadership |
Atif Rizvi | VP, Finance | Leadership |
Tom Ippolito | Vice President, Quality and Regulatory Affairs | Leadership |
Stella Rivera | VP, Human Resources | Leadership |
Neil A. Goldman | Executive Vice President & CFO | Leadership |
Javan Esfandiari | Executive Vice President & Chief Science and Technology Officer | Leadership |
Patrick Galvin | U.s. Director Of Sales | Leadership |
Moira Bilich | Sr. Director Qa/qc | Leadership |
Angelo Gunasekera | Senior Director Of R&d | Leadership |
Anita John | Director Of Finance | Leadership |
Robert Gannon | Director, Channel Strategy And Partnerships | Leadership |
Adam Hewitt | National Sales Director | Leadership |
David Smiley | Laboratory Technician | Team |
Yusuf K. | Senior Regulatory Affairs Specialist | Team |
Jonovan Acosta | Senior Manager - Public Health | Team |
Raquel Corl | Sales Development Representative | Team |
Renata Fernandes | Analista Financeiro Sênior | Team |
Jean Marie Marchant Busceti | Research Scientist | Team |
Bill Schneider | Sr. Manager, Manufacturing Reliability & Projects | Team |
David Greenwald | Tech Sup. | Team |
4 more people are available in the full profile.
Complete people profiles for Chembio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Chembio
Chembio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Orangelife Comercio E Industria.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Diagnostic test kits are manufactured for healthcare applications. | orangelife.com.br | – | 2011 | Nov 2019 | •••• |
Complete acquisition details for Chembio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Chembio
6 dated milestones of Chembio across 37 years, from founding to its latest funding, stage changes and deals.
- Founded Chembio is founded.
- Funding First funding round of $2.8M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Debt – Conventional, of $20.0M.
- Acquisition Acquires Orangelife Comercio E Industria.
- Exit Acquired by Biosynex.
Competitors of Chembio
Chembio has 8 listed competitors in our database, 7 of them funded. They include Souzhou Ribo Life Science, PathoQuest, Quantalife, Senzo and Hememics Biotechnologies, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ribolia.com | 2007 | Suzhou, China | $200.79M | – | Nucleic acid drugs are developed via RNA interference technology. | |
| pathoquest.com | 2010 | Paris, France | $9.99M | – | Next-generation sequencing is provided for microbiology testing applications. | |
| quantalife.com | 2008 | Pleasanton, United States | $28.71M | – | Provide tools that accelerate new strategies for the diagnosis and treatment of inherited disorders, cancer, and infectious disease. | |
| senzo.com | 2013 | San Francisco, United States | $9.6M | 13 | Point-of-care diagnostic devices for infectious diseases are developed. | |
| hememics.com | 2009 | Gaithersburg, United States | $4.6M | 13 | Biopreservation platform for mammalian cells and biologics is developed. | |
| daktaridx.com | 2008 | Boston, United States | $73.42M | 23 | Point of care diagnostic platform and data management system | |
| e25bio.com | 2018 | Cambridge, United States | $4.8M | 5 | Diagnostic platform for disease detection and mapping is provided. | |
| matridx.com | 2019 | Hangzhou, China | – | – | Sequencing-based platform for microorganism detection in patients is developed. |
Detailed competitors of Chembio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Chembio
The website of Chembio (chembio.com) receives about 4K visits a month.
- Monthly visits4K
▼ 37.8% vs previous month
Websites whose visitors overlap most with Chembio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
newswise.com | newswise.com | 100% | – | #309,012 | – |
| cdc.gov | 100% | 16.4M | #4,309 | View details | |
| biomerieux-diagnostics.com | 89% | – | – | View details | |
| calypte.com | 89% | – | – | View details | |
| idsplc.com | 69% | 5.1K | #4,586,165 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Chembio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
10 companies that operate in the same segment as Chembio (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chembio
Complete news archive for Chembio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chembio
Chembio was founded in 1986 and raised its 1st funding round 21 years after it was founded.
Chembio is headquartered in Medford, United States. It is registered at Medford, Oregon, United States.
Richard Eberly is the current CEO of Chembio.
Chembio has 213 employees.
Annual revenue of Chembio is $49.52M as on Dec 31, 2022.
Chembio Diagnostics, Inc. was established in 1986 in Medford, United States, within the medical diagnostics sector. Rapid tests for infectious diseases, including two FDA PMA-approved, CLIA-waived HIV assays, are produced using the patented Dual Path Platform technology. In the U.S., these HIV tests are distributed by Alere, Inc. Internationally, the HIV STAT-PAK line is supplied to government and donor-funded programs through direct sales and distributors.
Chembio's top competitors include Souzhou Ribo Life Science, Quantalife and Senzo.
Chembio offers DPP HIV-Syphilis Assay, DPP HIV 1/2 Assay, SURE CHECK HIV Self-Test, DPP Zika IgM/IgG System, and Advin COVID-19 Antigen Test.
Chembio has made 1 acquisition, including Orangelife Comercio E Industria.
Chembio has 3 investors. Key investors include HHS, Biosynex, and Perceptive Advisors.
Chembio operates through Chembio Diagnostics, Inc..
Yes. Chembio was acquired by Biosynex in January 2023.